Oesorite-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed to manage gastrointestinal disorders involving acid reflux and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), effectively suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme in the gastric parietal cells, providing symptomatic relief in conditions like gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome. The synergistic action of these agents addresses both acid-related mucosal damage and impaired gastric motility, enhancing therapeutic outcomes. Oesorite-DSR is indicated for patients with symptomatic GERD accompanied by delayed gastric emptying or dyspeptic symptoms. It should be administered orally, preferably before meals, as directed by a healthcare professional. Caution is advised in patients with known hypersensitivity to either component, underlying cardiac conditions, or hepatic impairment. Regular monitoring and adherence to prescribed dosage ensure optimal efficacy and minimize adverse effects such as headache, dry mouth, or gastrointestinal disturbances. This combination capsule offers a comprehensive approach to managing complex upper gastrointestinal disorders.